Anticancer evidence for zoledronic acid across the cancer continuum

Critical Reviews in Oncology/Hematology

Volumn 77, Issue SUPPL.1, 2011, Pages

  Costa, Luis ^a   Harper, Peter ^b   Coleman, Robert E ^c   Lipton, Allan ^d  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Anticancer; Bone metastasis; Cancer; Clinical trial; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; CLODRONIC ACID; DOCETAXEL; GOSERELIN; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; VASCULOTROPIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; GAMMA DELTA T LYMPHOCYTE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MENOPAUSE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW; TUMOR REGRESSION;

BONE DENSITY CONSERVATION AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79951842507     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(11)70006-3     Document Type: Review

References (58)

1. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
2. Boyle WJ, Simonet WS, Lacey DL Osteoclast differentiation and activation. Nature 2003, 423:337-342.
3. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
4. Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
5. Zometa (zoledronic acid) injection [package insert] 2008, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
6. Bonefos (disodium clodronate) [package insert] 2008, Bayer Schering Pharma, Oy, Turku, Finland.
7. Aredia (pamidronate disodium) injection [package insert] 2008, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
8. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
10. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603-609.
11. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Poster presented at American Society of Clinical Oncology Breast Cancer Symposium, 2009 [abstract 213].
12. Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, Sikov WM, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J Clin Oncol 2008, 26(Suppl):9s. [abstract 512].
13. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new métastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
14. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
15. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
16. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
17. Ha TC, Li H Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007, 96:1796-1801.
18. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
19. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008, 26(Suppl):20s. [abstract 559].
20. Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at 31st Annual San Antonio Breast Cancer Symposium, 2008 [abstract 2048].
21. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-Macgregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
22. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
23. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010, 21:2188-2194.
24. Coleman R, Bundred N, de Boer R, Llombart A, Campbell I, Neven P, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at 32nd Annual San Antonio Breast Cancer Symposium, 2009 [abstract 4082].
25. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
26. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengrueth G, Poestlberger S, Dubsky PC, et al. Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010, 28(Suppl):74s. [abstract 533].
27. Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at 33rd Annual San Antonio Breast Cancer Symposium, 2010 [abstract S4-5].
28. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone métastases in patients with recurrent solid tumors that did not present with bone métastases at baseline. Med Oncol 2005, 22:195-201.
29. Zaghloul MS, Boutros R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010, 15:382-389.
30. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125:1705-1709.
31. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24:227-230.
32. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
33. Gnant M Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drag Targets 2009, 9:824-833.
34. Green JR, Guenther A The backbone of progress - preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 2011, 77(1):S3-12.
35. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58:31-38.
36. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13:4482-4486.
37. Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkko-nen J, et al. Zoledronic acid-induced IPP/ApppI (phosphoantigen) accumulation in human breast cancer cells correlates with Vγ9Vδ2 T cell-mediated cancer cell death in vitro and in vivo. Presented at International Bone and Mineral Society Meeting, 2010 [abstract 93].
38. Clezardin P, Ebetino FH, Fournier PGJ Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005, 65:4971-4974.
39. Normanno N, Gallo M, Lamura L, De Luca A Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment. J Clin Oncol 2010, 28(Suppl):748s. [abstract 10602].
40. Norton L, Massague J Is cancer a disease of self-seeding?. Nat Med 2006, 12:875-878.
41. Clines GA, Guise TA Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008, 10:e7.
42. Meads MB, Hazlehurst LA, Dalton WS The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
43. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22:941-950.
44. Paget S The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
45. Lipton A, Zheng M, Seaman J Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:962-969.
46. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al. Normalization of bone markers is associated with improved survival in patients with bone métastases from solid tumors and elevated bone résorption receiving zoledronic acid. Cancer 2008, 113:193-201.
47. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE Zoledronic acid and survival in breast cancer patients with bone métastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
48. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236.
49. Body J-J, Cook R, Costa L, Brown J, Terpos E, Saad F, et al. Possible survival benefits from zoledronic acid treatment in patients with bone métastases from solid tumors and poor prognostic features. Presented at XI International Meeting on Cancer Induced Bone Disease, 2009 [abstract 71].
50. Saad F, Lipton A, Cook R, Chen Y-M, Smith M, Coleman R Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
51. Calderone RG, Nimako K, Leary AN, Popat S, Kipps E, O'Brien MN Use of zoledronic acid in lung cancer. J Thorac Oncol 2010, 5(Suppl 1):S99-S100. [abstract 253P].
52. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 2010, 10:543-548.
53. Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Schenk N, et al. Effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST/ZO-FAST trials. Presented at Primary Therapy of Early Breast Cancer 11th International Conference, 2009 [abstract 132].
54. Neville-Webbe HL, Gnant M, Coleman RE Potential anticancer properties of bisphosphonates. Semin Oncol 2010, 37(Suppl 1):S53-S65.
55. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human γδT cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007, 67:7450-7457.
56. Santini D, Fratto ME, Galluzzo S, Vincenzi B, Tonini G Are bisphosphonates the suitable anticancer drags for the elderly?. Crit Rev Oncol Hematol 2009, 69:83-94.
57. Saad F, Lipton A Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone métastases secondary to genitourinary cancers. BJU Int 2005, 96:964-969.
58. Morgan GJ Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?. Crit Rev Oncol Hematol 2011, 77(1):S24-S30.